What role does tigecycline's patent play in its high cost?

Tigecycline's patent protection blocks generic versions from entering the market, allowing its maker to maintain sole control over pricing until the patent expires.

Why do companies challenge this patent?
The current owner faces multiple legal challenges to tigecycline's patents. Companies seeking to launch generics file paragraph IV certifications against the key patents listed in the Orange Book. These challenges focus on claims covering the composition, manufacturing process, and extended-release formulations.

When does patent expire?
The primary composition-of-matter patent for tigecycline expires in 2025, with additional patents covering manufacturing methods and formulations extending protection through 2028 in some cases. [1]

How long does exclusivity last?
Regulatory exclusivity periods granted by the FDA add further delay to generic competition beyond the patent term. These periods include five-year new chemical entity exclusivity and three-year new clinical investigations exclusivity.

What alternatives exist before patent expiry?
Before full generic entry, hospitals often use older tetracyclines such as doxycycline or minocycline as cheaper alternatives for susceptible infections. In severe cases, physicians may switch patients to meropenem or piperacillin-tazobactam when resistance patterns demand other options.

Why is the drug priced so high?
Patent exclusivity prevents price competition. The absence of generics means the original manufacturer can set prices based on the drug's utility in treating multidrug-resistant bacteria rather than on competitive market pricing.

Can biosimilars enter before patent expiry?
Tigecycline is a small-molecule drug rather than a biologic, therefore biosimilars are not applicable. Generic small-molecule versions will appear once the patents and regulatory exclusivities lapse.

DrugPatentWatch.com